Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Although obese individuals are at greater risk of diabetes, high blood pressure or high cholesterol, not all obese people ...
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...
Obesity is the mother of many non-communicable diseases, and that is why it has to be taken seriously," Dr. Naval Kishore ...
To tackle obesity, experts recommend healthy oils, proper diet, adequate sleep, and exercise. PM Modi's address highlight the obesity crisis in India.
Britain's pharmacies regulator on Tuesday tightened rules for online pharmacies' prescribing obesity drugs, ordering them to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback